Lung Cancer Clinical Trials in Los Angeles, CA

Lung Cancer Clinical Trials in Los Angeles, CA

View the best 10 lung cancer medical studies in Los Angeles, California. Access promising new therapies by applying to a Los Angeles-based Lung Cancer clinical trial.

Trials in Los Angeles, California

Here are the top 10 medical studies for lung cancer in Los Angeles, California

Image of Research Site in Chandler, United States.

Docetaxel +2 More

Taxane

Recruiting3 awardsPhase 3
This trial tests a new combination of drugs (ceralasertib and durvalumab) against a standard treatment (docetaxel) in patients with advanced lung cancer who didn't respond to previous treatments. The new combination aims to weaken cancer cells and boost the immune system, while the standard treatment directly kills the cancer cells.
Image of 1004 in Denver, United States.

BDTX-1535

Small Molecule Inhibitor

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug for people with glioblastoma or non-small cell lung cancer who have disease progression following standard of care.
Image of University of Southern California, Norris Comprehensive Cancer Center in Los Angeles, United States.

Carboplatin +4 More

Chemotherapy

Recruiting1 awardPhase 1
This trial is testing a new drug called tarlatamab combined with treatments that help the immune system fight cancer, and sometimes with chemotherapy. It targets cancer patients who need new treatment options. Tarlatamab attacks cancer cells directly, while other treatments boost the immune response or kill cancer cells.
Image of I.H.S Health, LLC in Kissimmee, United States.

Treatment

Recruiting1 award4 criteria
This trial is testing a blood test to see if it can detect lung cancer early in high-risk individuals. Blood samples will be collected from participants who are getting a routine CT scan for lung cancer screening.
Image of Loyola Marymount University in Los Angeles, United States.

Mindful Self-Compassion for Lung Cancer (MSC-LC)

Behavioral Intervention

Recruiting1 award
This trial is testing a mindfulness-based program called Mindful Self-Compassion for Lung Cancer (MSC-LC) in adults with lung cancer who experience stigma. The goal is to see if this
Image of Sarcoma Oncology in Santa Monica, United States.

HBI-2438

Epigenetic Modulator

Recruiting1 awardPhase 1
This trial tests HBI-2438, an oral drug for patients with advanced solid tumors having the KRAS G12C mutation. The drug aims to stop cancer growth by blocking the faulty gene. Related drugs, Adagrasib and Sotorasib, have shown effectiveness in treating similar conditions.
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Carotuximab +1 More

Monoclonal Antibodies

Recruiting2 awardsPhase 1
This trial is testing a combination of two drugs, osimertinib and carotuximab, to treat advanced EGFR-mutated non-small cell lung cancer. The goal is to find the maximum tolerated dose of the combination by measuring the number of dose-limiting toxicities. Secondary objectives include evaluating the rate of objective response, duration of response, progression-free survival, and disease control rate.
Image of City of Hope in Duarte, United States.

ELI-002 7P

Recruiting1 awardPhase 1 & 2
This trial is testing a new treatment called ELI-002 7P for patients with specific types of cancer. The treatment helps the immune system recognize and attack these cancer cells. ELI-002 7P targets mutations that are common in various cancers and have been studied for their role in tumor growth and resistance to treatments.
Image of ArriVent Investigative Site in Fairfax, United States.

Platinum-based Chemotherapy +1 More

Alkylating agents

Recruiting2 awardsPhase 3
This trial is testing furmonertinib at two different doses to treat a specific type of lung cancer. It targets patients with advanced or metastatic non-squamous NSCLC who have a particular genetic mutation. The medication works by blocking a protein that helps cancer cells grow, potentially slowing down or stopping the cancer.
Image of Valkyrie Clinical Trials, Inc. in Los Angeles, United States.

Tislelizumab +2 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial is testing a new drug and chemotherapy combo to treat lung cancer, depending on how much of a certain protein is expressed.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.